The Value of Modular Design in Pharma-Grade ODF Production Lines

Scale smoothly from R&D to commercial production while maintaining data continuity and GMP readiness.

Introduction

In pharmaceutical and functional food manufacturing, Oral Dissolvable Film (ODF) lines must support a full lifecycle—from early R&D and pilot validation to commercial-scale production. The challenge is ensuring a smooth transition between stages without re-engineering the process or duplicating investments. A modular ODF production design addresses this by enabling stepwise expansion on a common technical backbone.

Why Modular Design Matters

• Lower upfront investment: Start with pilot or mid-scale modules instead of a full large-scale line.
• Support process validation: Validate on a pilot line first, then scale up with consistent principles.
• Flexible expansion: Add or swap modules (coating, drying, slitting, packaging) as capacity grows.

Common Industry Pain Points

• One-size-fits-all lines: Different equipment for R&D, pilot, and commercial stages leads to repeated CAPEX.
• Process gaps across scales: Parameter drift between small and large equipment complicates registration and validation.
• Long scale-up cycles: Without modularity, every expansion requires fresh procurement, installation, and commissioning.

Huanghai’s Modular Approach

• Modular line layout: Core stages—coating, drying, slitting, and packaging—can be deployed in phases to fit current needs.
• Smooth R&D→commercial transfer: The pilot model MJ150-L and the commercial model MJ150 share the same process logic, improving data comparability and continuity.
• Reduced validation risk: Consistent design principles help minimize variability during scale-up and support GMP audits.

Quality & Compliance Value

• Traceability & consistency: Maintain aligned controls and documentation across stages.
• Registration-ready data: Generate continuous, comparable data sets for process validation and filing.
• Lifecycle agility: Improve flexibility and cost efficiency from development through commercialization.

Recommended Equipment

MJ150-L — Pilot/R&D Coating Machine

• Designed for development and pilot validation
• Process logic aligned with MJ150 for data continuity

View MJ150-L

MJ150 — Commercial Coating Machine

• Commercial-scale output for ODF and solvent-based patch films
• Built for GMP environments and scalable operations

View MJ150

MJF180 — ODF Slitting & Packaging

• Precise slitting and single-dose packaging
• Supports efficient downstream operations and stability

View MJF180

Conclusion

Modular design brings flexibility, scalability, and compliance support to pharma-grade ODF manufacturing. Each step—from R&D to commercial production—can progress on the same technical logic, reducing investment risk, shortening expansion timelines, and accelerating the journey from development to market.

*Features Huanghai's exclusive patented hot-air drying technology (Patent No. CN201668734U) ensuring uniform bottom-up heating.

---

Frequently Asked Questions

Q: What is the difference between an ODF film and a transdermal patch?

A: Oral Dissolving Films (ODF) are placed on or under the tongue and dissolve within seconds to minutes, delivering APIs directly through the oral mucosa or via swallowing. Transdermal patches adhere to the skin and deliver APIs through the dermal layers into systemic circulation over hours to days. Despite different delivery routes, both are manufactured using similar solvent-cast film coating processes. Huanghai's MJ150 ODF machine supports both applications on a single platform with approximately 2 working days of changeover time.

Q: What production output can I expect from a Huanghai ODF machine?

A: The MJ150 produces 20,000 films/hour at commercial scale. The MJ150-L targets R&D and pilot production at 8,000–10,000 films/hour. For fully integrated lines, pair either machine with the MJF180 automatic cutting and packaging system (11,900 films/hr) or the more affordable EZ320 (9,000 films/hr). A complete MJ150 + MJF180 line can produce over 150 million finished pouches annually on a single-shift basis. Contact us for pricing and configuration details.

Q: What drying technology does Huanghai use for ODF production?

A: Huanghai uses patented gradient hot-air drying (Patent CN201668734U), which applies a smooth progressive temperature drop rather than stepwise oven zones used by competitors. This results in more uniform film thickness, reduced edge curl, and better API distribution across the film web. An optional far-infrared heating module adds 20–30% drying efficiency for solvent-based formulations. This patented drying system is one of the key technical advantages that justifies Huanghai's position as the preferred ODF equipment supplier to Sinopharm, Shanghai Pharma, and Fosun Pharma.

Q: What are the GMP requirements for ODF production equipment?

A: ODF manufacturing equipment must comply with cGMP (21 CFR Parts 210/211) for US market products, and equivalent standards (EU GMP Annex 1, ChGMP) for other markets. Key requirements: material contact surfaces must be 316L stainless steel or equivalent; CIP/SIP capability or documented cleaning validation; data integrity controls meeting ALCOA+ principles (audit trails, access control). Huanghai ODF machines meet these standards—all product contact surfaces use pharmaceutical-grade materials, and the control system includes operator access logs and parameter change records. Request our GMP compliance documentation.

For a full overview of the certifications and compliance standards our equipment meets, see our Certifications & Compliance page.

Q: Can Huanghai machines produce stripe-coated or multi-formula ODF films?

A: Yes. Huanghai holds a patent for multi-formula stripe coating (Patent CN117323228A), enabling two different API formulations to be applied side-by-side in a single coating pass. This eliminates the need for multiple coating/drying cycles when producing combination-drug ODF products. Competitors require manual multi-layer coating with drying intervals between each formula. This capability is particularly valuable for fixed-dose combination products (e.g., dual-API ODFs for cardiovascular or CNS indications) where coating efficiency directly impacts production economics.